Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day

Sexually Transmitted Diseases

Volumn 28, Issue 4, 2001, Pages 226-231

  Fife, Kenneth H ^a,f   Ferenczy, Alex ^b   Douglas Jr , John M ^c   Brown, Darron R ^a,d   Smith, Michael ^e   Owens, Mary L ^e   Beutner, Karl ^f   Poretz, Donald ^f   Reichman, Richard ^f   Sperling, Malcom ^f   Spruance, Spotswood ^f  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c Denver Disease Control Service   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e 3M COMPANY   (United States)

^f Emerson Hall 435 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD;

ADULT; AGED; ARTICLE; CANDIDA; CLINICAL TRIAL; CONDYLOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DRUG EFFICACY; ERYTHEMA; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; SKIN BIOPSY; SKIN ULCER; TREATMENT OUTCOME; UNITED STATES;

EID: 0035085156     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007435-200104000-00007     Document Type: Article

References (20)

1. External genital warts: Report of the American Medical Association consensus conference
2. Induction of interferon and other cytokines by imiquimod and its hydroxylated metabolite R-842 in human blood cells in vitro
3. Cytokine induction by the immunomodulators imiquimod and S-27609
4. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts
5. Self-administered topical 5% imiquimod cream for external anogenital warts
6. Treatment of genital warts with an immune-response modifier (imiquimod)
7. Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification
8. Use of human papillomavirus type 6 capsids to detect antibodies in people with genital warts
9. Epidemiology of genital human papillomavirus infection
10. Genital warts and their treatment
11. Treatment of external genital warts: A randomised clinical trial comparing podophyllin, cryotherapy, and electrodesiccation
12. Effect of a novel topical immunomodulator, S-28463, on keratinocyte cytokine gene expression and production
13. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod
14. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463
15. Parameters of interferon action: I. Immunological effects of whole cell leukocyte interferon (IFN-alpha) in phase I-II trials
16. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies
17. Induction of tolerance allows separation of lethal and antitumor activities of tumor necrosis factor in mice
18. A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily
19. Immunological events in regressing genital warts